济民药业,关爱无限 www.pidrug.com
香港济民药业微信二维码
198 9654 1773
当前位置:首页 > 药品资讯 > 精神科 > 艾司佐匹克隆eszopiclone

艾司佐匹克隆eszopiclone

[ 人气:166 | 日期: 2020-08-04 | 返回 | 打印 ]
艾司佐匹克隆eszopiclone
药品名称:艾司佐匹克隆eszopiclone
药品别名:右佐匹克隆; 右旋佐匹克隆; 埃佐匹克隆; 艾司佐匹
英 文 名:eszopiclone
药品价格:$ 请咨询微信客服
研发公司:
适 用 症:用于入睡困难,夜间维持睡眠困难、早醒等不同类型的睡眠障碍
型号规格:本品为片剂,每片含有效成份1mg/2mg/3mg,每瓶100片装。
药品详情:

【艾司佐匹克隆eszopiclone 简述】
 
     艾司佐匹克隆eszopiclone又名右佐匹克隆; 右旋佐匹克隆; 埃佐匹克隆; 艾司佐匹; 本品为环毗咯的吡咯吡嗪衍生物。

艾司佐匹克隆eszopiclone_香港济民药业
 
【艾司佐匹克隆eszopiclone 适应症】
 
    艾司佐匹克隆可用于入睡困难,夜间维持睡眠困难、早醒等不同类型的睡眠障碍。
 
【艾司佐匹克隆eszopiclone 规格】
 
    本品为片剂,每片含有效成份1mg/2mg/3mg,每瓶100片装。
 
【艾司佐匹克隆eszopiclone 服用方法】
 
    艾司佐匹克隆应个体化给药。对于大多数成年患者的起始剂量为睡前给予2~3 mg,对于老年患者建议起始剂量为1~2 mg。有严重肝功能损害者的起始剂量为1 mg,对于与CYP3A4抑制剂合用者,起始剂量不应该超过1 mg.老年患者服用本品的起始剂量不应超过2 mg。肝功能异常者应慎用本品。严重肝功能异常者服用本品不应超过2 mg。肾功能异常者无需调节剂量。
 
【艾司佐匹克隆eszopiclone 注意事项】
 
    本品与帕罗西汀、地高辛和华法林之间无相互作用。本品与奥氮平合用时不改变相互之间的药动学。劳拉西洋合用时两者的ρmax可减少22%。本品当本品与CYP3A4抑制剂酮康唑合用时,可增加本品的ρmax2.2倍。本品不改变由 CYP450酶系统代谢的药物的清除率。
 
【艾司佐匹克隆eszopiclone 不良反应】
 
    艾司佐匹克隆有较好的耐受性,常见的不良反应是味觉异常、头晕、胸痛、偏头痛。本品不产生依赖性,很少引起记忆损害。

eszopiclone

 
Eszopiclone, sold under the brand-name Lunesta, is a medication used in the treatment of insomnia.[2][2]
 
It is a nonbenzodiazepine hypnotic agent. Eszopiclone is the active dextrorotatorystereoisomer of zopiclone, and belongs to the class of drugs known as cyclopyrrolones. It is also classified as a therapeutic sedative hypnotic and pharmacological cyclopyrrolone.[3]
 
Eszopiclone is not marketed in the European Union following a 2009 decision by the EMAdenying it new active substance status,[4] in which it ruled that eszopiclone was too similar to zopiclone to be considered a new patentable product.[5] Eszopiclone is now available in a generic form in the United States as of May 2014. On May 15, 2014, the USFDA asked that the starting dose of Eszopiclone (Lunesta) be lowered from 2 milligrams to 1 milligram after it was observed in a study that even 8 hours after taking the drug at night, some patients were not able to cope with their next-day activities like driving and other activities that require full alertness.[6] It works by interacting with the GABA receptors.[3]
 
In 2016 it was the 286th most prescribed medication in the United States with more than a million prescriptions.[7]
 
Medical uses
 
A Cochrane report published October 2018 found that eszopiclone produces moderate improvement in sleep onset and maintenance. The authors suggest that where preferred non-pharmacological treatment strategies have been exhausted, eszopiclone provides an efficient treatment for insomnia.[8]
Eszopiclone is slightly effective in the treatment of insomnia where difficulty in falling asleep is the primary complaint.[2] Kirsch et al. found the benefit over placebo to be of questionable clinical significance.[2] Although the drug effect and the placebo response were rather small and of questionable clinical importance, the two together produce a reasonably large clinical response.[2] It is not recommended for chronic use in the elderly.[9]
Elderly
Sedative hypnotic drugs including eszopiclone are more commonly prescribed to the elderly than to younger patients despite benefits of medication being generally unimpressive. Care should be taken in choosing an appropriate hypnotic drug and if drug therapy is initiated it should be initiated at the lowest possible dose to minimise side effects.[10]
In 2015, the American Geriatrics Society reviewed the safety information about eszopiclone and similar drugs and concluded that the "nonbenzodiazepine, benzodiazepine receptor agonist hypnotics (eszopiclone, zaleplon, zolpidem) are to be avoided without consideration of duration of use because of their association with harms balanced with their minimal efficacy in treating insomnia."
 
The review made this determination both because of the relatively large dangers to elderly individuals from zolpidem and other "z-drugs" together with the fact the drugs have "minimal efficacy in treating insomnia." This was a change from the 2012 AGS recommendation, which suggested limiting use to 90 days or less. The review stated "the 90‐day‐use caveat [was] removed from nonbenzodiazepine, benzodiazepine receptor agonist hypnotics, resulting in an unambiguous 'avoid' statement (without caveats) because of the increase in the evidence of harm in this area since the 2012 update." [11]
 
An extensive review of the medical literature regarding the management of insomnia and the elderly found that there is considerable evidence of the effectiveness and durability of non-drug treatments for insomnia in adults of all ages and that these interventions are underutilized. Compared with the benzodiazepines, the nonbenzodiazepine sedative-hypnotics, including eszopiclone appeared to offer few, if any, significant clinical advantages in efficacy or tolerability in elderly persons. It was found that newer agents with novel mechanisms of action and improved safety profiles, such as the melatonin receptor agonists, hold promise for the management of chronic insomnia in elderly people. Long-term use of sedative-hypnotics for insomnia lacks an evidence base and has traditionally been discouraged for reasons that include concerns about such potential adverse drug effects as cognitive impairment (anterograde amnesia), daytime sedation, motor incoordination, and increased risk of motor vehicle accidents and falls. In addition, the effectiveness and safety of long-term use of these agents remain to be determined. It was concluded that more research is needed to evaluate the long-term effects of treatment and the most appropriate management strategy for elderly persons with chronic insomnia.[12]
 
A 2009 meta-analysis found a higher rate of infections.[13]
 
 
Adverse effects
 
Sleeping pills, including eszopiclone, have been associated with an increased risk of death.[14]
 
Hypersensitivity to eszopiclone is a contra-indication to its use. Some side effects are more common than others. Recommendations around use of eszopiclone may be altered by other health conditions. These conditions or circumstances may occur in people that have lowered metabolism and other conditions. The presence of liver impairment, lactation and activities requiring mental alertness (e.g. driving) may be considered when determining frequency and dosage.[3]
§                                 unpleasant taste[3]
§                                 headache[3]
§                                 peripheral edema[3][15]
§                                 chest pain[3]
§                                 abnormal thinking[3]
§                                 behavior changes[3]
§                                 depression[3][15]
§                                 hallucinations[3][15]
§                                 sleep driving[3] and sleepwalking
§                                 dry mouth[3]
§                                 rash[3][15]
§                                 altered sleep patterns[3]
§                                 impaired coordination[3]
§                                 dizziness[3]
§                                 daytime drowsiness[3]
§                                 itching[15]
§                                 painful or frequent urination[15]
§                                 back pain[15]
§                                 aggressive behavior[15]
§                                 confusion[15]
§                                 agitation[15]
§                                 suicidal thoughts[15]
§                                 depersonalisation[15]
§                                 amnesia[15]
 
A 2009 meta-analysis found a 44% higher rate of mild infections, such as pharyngitis or sinusitis, in people taking Eszopiclone or other hypnotic drugs compared to those taking a placebo.[16]
 
Overdose
 
According to the U.S. Prescribing Information, overdoses of eszopiclone up to 90 times the recommended dose have been reported in which the patient fully recovered. According to the May 2014 edition of the official U.S. Prescribing Information, fatalities have been reported only in cases in which eszopliclone was combined with other drugs or alcohol.[18]
Texas poison control centers reported that during 2005–2006 there were 525 total eszopiclone overdoses recorded in the state of Texas, the majority of which were intentional suicide attempts.[19]
 
If consumed within the last hour, eszopiclone overdose can be treated with the administration of activated charcoal or via gastric lavage.[20]
 
 




注:药品如有新包装,以新包装为准。以上资讯仅供医护人员内部讨论,不作任何用药依据,具体用药指引,请咨询主治医师。

更多相关资讯:返回顶部
最新药品资讯
  • 乙肝新药TAF替诺福韦适用人群是哪些?需要注意什么?
  • 美国FDA加速批准新型ADC药物Padcev,用于治疗膀胱癌PD-(L)1抑制剂和化疗难治患者!
  • 美国FDA批准非霍奇金淋巴瘤新药Polivy上市!
  • Entocort EC布地奈德胶囊(Budesonide)获FDA批准,用于Crohn病
  • 乐伐替尼(Lenvima)用法用量及注意事项详解
  • 帕博西尼palbociclib联合芳香化酶抑制剂(letrozole)治疗乳腺癌安全性如何?
  • Opdivo+Cabometyx方案治疗晚期肾细胞癌(RCC)获美国FDA优先审查!
  • 艾伯维抗癌药Venclexta获美国FDA完全批准治疗新诊断的急性髓性白血病成人患者
  • 晚期乳腺癌临床试验:玻玛西林/瑞博西尼可改善患者总生存期!
  • Tremfya(特诺雅®)获欧盟CHMP推荐批准治疗银屑病关节炎(PsA)成人患者,中国已上市!
  • CHMP建议批准Vocabria联合Rekambys用于HIV-1,可1或2个月注射一次!
  • 安归宁Agrylin治疗血小板增多症效果惊人!
  • 玻玛西林Verzenio治疗绝经后HR阳性,HER2阴性晚期或患有转移性乳腺癌最常见的不良反应有哪些?
  • 抗PD-1疗法Keytruda联合化疗治疗NSCLC的最长随访数据:完成2年Keytruda治疗的患者中,3年生存率达92%!
  • 欧盟CHMP推荐批准Opdivo(欧狄沃)治疗食管鳞状细胞癌(ESCC):二线治疗显著延长了总生存期!
  • PI3K抑制剂Aliqopa(Copanlisib)联合利妥昔单抗治疗惰性非霍奇金淋巴瘤显著延长PFS!
  • 赛诺菲Dupixent(达必妥)获国家药监局批准:治疗中重度特应性皮炎成人患者!
  • 乐伐替尼Lenvima治疗肝细胞癌(HCC)总体响应率高于索拉非尼!
  • Nintedanib(尼达尼布)的八个版本
  • Nintedanib(尼达尼布)治疗肺纤维化(IPF)在印度获批上市!
  • 胶质母细胞瘤下一代抗体偶联药物Trodelvy获FDA孤儿药资格!
  • Inmazeb获FDA批准:治疗埃博拉病毒感染,大幅降低死亡率!
  • Entocir (budesonide) 布地奈德说明书-价格-功效与作用-副作用
  • Pacritinib在美申请上市:治疗伴有严重血小板减少症的骨髓纤维化
  • HIV新药DovatoⅢ期临床96周数据:长期疗效相似TAF多药方案
  • 新型的铁载体头孢菌素Fetroja:有效治疗耐多药革兰氏阴性菌感染!
  • 恩替卡韦VS替诺福韦(TAF),有哪些差别?
  • Evrysdi (risdiplam) 治疗2-7个月儿童脊髓性肌萎缩研究试验获积极结果!
  • 抗炎药Dupixent(达必妥)治疗6-11岁不受控哮喘儿童患者的关键3期临床试验成功!
  • 第三款RNAi药物lumasiran治疗原发性高草尿酸症1型儿科3期研究获成功!


  • 如您发现本网站有文字编辑或内容错误,请点击此处发送(需要安装有foxmail或outlook支持),


    或发邮件至:info@morecare.hk,香港济民药业感谢您的到访!


    欢迎您添加香港济民药业微信,或在公众号内留言。

    香港济民微信公众号
    • 香港济民药业友情链接
    • 友情链接

    联系我们:

    地址:
    Rm. 314, Sun Ling Plaza, 30 On Kui Street, Fanling, HONG KONG
    邮箱:
    info@pidrug.com
    电话:
    198 9654 1773
    粤ICP备17150936号
    香港济民药业官方网站
    • 关注我们 :
    • 香港济民药业微博
    • 关注香港济民药业博客
    • 香港济民药业微信公众号